In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other penny stocks with the biggest upside potential. Penny stocks trade below $5 and attract ...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...

GOSSAMER BIO ($GOSS) is expected to release its quarterly earnings data on Friday, March 21st after market close, per Finnhub. Analysts are expecting revenue of ...

Gossamer Bio has a one year low of $0.50 and a one year high of $1.60. The stock has a market cap of $278.72 million, a PE ratio of -3.84 and a beta of 1.81. The firm has a 50 day simple moving ...

Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Gossamer Bio in a report issued on Monday, March 24th.

Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. These figures are ...